NCT06561152View on ClinicalTrials.gov

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 10, 2025

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2028

Conditions
Refractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia
Interventions
DRUG

Tagraxofusp

Tagraxofusp is administered by intravenous infusion (IV) over 15 minutes for 3 consecutive days of a 28-day cycle. (days 4-6)

DRUG

Cladribine (CLAD)

Cladribine 5mg/m2 IV once daily on days 1-3 (DL1) Cladribine 5mg/m2 IV once daily on days 1-4 (DL2) Cladribine 5mg/m2 IV once daily on days 1-5 (DL3)

DRUG

Cytarabine

Cytarabine 20mg/m2 IV daily days 1-5 (DL1) Cytarabine 20mg/m2 IV daily days 1-7(DL2) cytarabine 20mg/m2 IV daily days 1-10 (DL3)

Trial Locations (1)

94304

RECRUITING

Stanford University, Palo Alto

All Listed Sponsors
collaborator

Stemline Therapeutics, Inc.

INDUSTRY

lead

Stanford University

OTHER